{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:43:55Z","timestamp":1790023435416,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007962","name":"Jikei University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urolonc.2025.02.007","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:34:25Z","timestamp":1740803665000},"page":"336.e1-336.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter study"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Muramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Katsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetsugu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahito","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.02.007_bib0001","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"A new old target: androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.007_bib0002","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.007_bib0003","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"20","key":"10.1016\/j.urolonc.2025.02.007_bib0004","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and Docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.007_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.007_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000030277","article-title":"Prognosis of patients with prostate carcinoma presenting as nonregional lymph node metastases","volume":"61","author":"Furuya","year":"1998","journal-title":"Urol Int"},{"issue":"3","key":"10.1016\/j.urolonc.2025.02.007_bib0007","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pros.22750","article-title":"Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer","volume":"74","author":"Ost","year":"2014","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.007_bib0008","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the site of metastases on survival in patients with metastatic prostate cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.007_bib0009","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.clgc.2018.05.016","article-title":"Location of metastases in contemporary prostate cancer patients affects cancer-specific mortality","volume":"16","author":"Mazzone","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2025.02.007_bib0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.007_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Pond","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.007_bib0012","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.007_bib0013","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2012.12.029","article-title":"Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms","volume":"64","author":"Omlin","year":"2013","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.urolonc.2025.02.007_bib0014","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.urolonc.2025.02.007_bib0015","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.02.007_bib0016","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2025.02.007_bib0017","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/cas.14722","article-title":"Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients","volume":"112","author":"Shiota","year":"2021","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.007_bib0018","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00345-022-03963-y","article-title":"Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy","volume":"40","author":"Narita","year":"2022","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.02.007_bib0019","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00345-022-04030-2","article-title":"Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis","volume":"41","author":"Yanagisawa","year":"2023","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.007_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pros.24243","article-title":"Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.007_bib0021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clgc.2023.08.004","article-title":"Overall survival of metastatic prostate cancer patients according to location of visceral metastatic sites","volume":"22","author":"Tappero","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2025.02.007_bib0022","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.007_bib0023","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JU.0000000000001568","article-title":"Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses","volume":"205","author":"Armstrong","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.007_bib0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.11.026","article-title":"Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: a post-hoc exploratory analysis of the LATITUDE study","volume":"162","author":"Baciarello","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.007_bib0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncr.30336","article-title":"Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and\/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial","volume":"123","author":"Loriot","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.007_bib0026","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clgc.2017.02.007","article-title":"Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with enzalutamide in the PREVAIL trial","volume":"15","author":"Alumkal","year":"2017","journal-title":"Clin Genitourin Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T16:03:11Z","timestamp":1746892991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1078143925000365"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}